Cargando…

A Circulating MicroRNA Signature as a Biomarker for Prostate Cancer in a High Risk Group

Introduction: Mi(cro)RNAs are small non-coding RNAs whose differential expression in tissue has been implicated in the development and progression of many malignancies, including prostate cancer. The discovery of miRNAs in the blood of patients with a variety of malignancies makes them an ideal, nov...

Descripción completa

Detalles Bibliográficos
Autores principales: Kelly, Brian D., Miller, Nicola, Sweeney, Karl J., Durkan, Garrett C., Rogers, Eamon, Walsh, Killian, Kerin, Michael J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4519795/
https://www.ncbi.nlm.nih.gov/pubmed/26239681
http://dx.doi.org/10.3390/jcm4071369
_version_ 1782383555669655552
author Kelly, Brian D.
Miller, Nicola
Sweeney, Karl J.
Durkan, Garrett C.
Rogers, Eamon
Walsh, Killian
Kerin, Michael J.
author_facet Kelly, Brian D.
Miller, Nicola
Sweeney, Karl J.
Durkan, Garrett C.
Rogers, Eamon
Walsh, Killian
Kerin, Michael J.
author_sort Kelly, Brian D.
collection PubMed
description Introduction: Mi(cro)RNAs are small non-coding RNAs whose differential expression in tissue has been implicated in the development and progression of many malignancies, including prostate cancer. The discovery of miRNAs in the blood of patients with a variety of malignancies makes them an ideal, novel biomarker for prostate cancer diagnosis. The aim of this study was to identify a unique expression profile of circulating miRNAs in patients with prostate cancer attending a rapid access prostate assessment clinic. Methods: To conduct this study blood and tissue samples were collected from 102 patients (75 with biopsy confirmed cancer and 27 benign samples) following ethical approval and informed consent. These patients were attending a prostate assessment clinic. Samples were reverse-transcribed using stem-loop primers and expression levels of each of 12 candidate miRNAs were determined using real-time quantitative polymerase chain reaction. miRNA expression levels were then correlated with clinicopathological data and subsequently analysed using qBasePlus software and Minitab. Results: Circulating miRNAs were detected and quantified in all subjects. The analysis of miRNA mean expression levels revealed that four miRNAs were significantly dysregulated, including let-7a (p = 0.005) which has known tumour suppressor characteristics, along with miR-141 (p = 0.01) which has oncogenic characteristics. In 20 patients undergoing a radical retropubic-prostatectomy, the expression levels of miR-141 returned to normal at day 10 post-operatively. A panel of four miRNAs could be used in combination to detect prostate cancer with an area under the curve (AUC) of 0.783 and a PPV of 80%. Conclusion: These findings identify a unique expression profile of miRNA detectable in the blood of prostate cancer patients. This confirms their use as a novel, diagnostic biomarker for prostate cancer.
format Online
Article
Text
id pubmed-4519795
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-45197952015-07-30 A Circulating MicroRNA Signature as a Biomarker for Prostate Cancer in a High Risk Group Kelly, Brian D. Miller, Nicola Sweeney, Karl J. Durkan, Garrett C. Rogers, Eamon Walsh, Killian Kerin, Michael J. J Clin Med Article Introduction: Mi(cro)RNAs are small non-coding RNAs whose differential expression in tissue has been implicated in the development and progression of many malignancies, including prostate cancer. The discovery of miRNAs in the blood of patients with a variety of malignancies makes them an ideal, novel biomarker for prostate cancer diagnosis. The aim of this study was to identify a unique expression profile of circulating miRNAs in patients with prostate cancer attending a rapid access prostate assessment clinic. Methods: To conduct this study blood and tissue samples were collected from 102 patients (75 with biopsy confirmed cancer and 27 benign samples) following ethical approval and informed consent. These patients were attending a prostate assessment clinic. Samples were reverse-transcribed using stem-loop primers and expression levels of each of 12 candidate miRNAs were determined using real-time quantitative polymerase chain reaction. miRNA expression levels were then correlated with clinicopathological data and subsequently analysed using qBasePlus software and Minitab. Results: Circulating miRNAs were detected and quantified in all subjects. The analysis of miRNA mean expression levels revealed that four miRNAs were significantly dysregulated, including let-7a (p = 0.005) which has known tumour suppressor characteristics, along with miR-141 (p = 0.01) which has oncogenic characteristics. In 20 patients undergoing a radical retropubic-prostatectomy, the expression levels of miR-141 returned to normal at day 10 post-operatively. A panel of four miRNAs could be used in combination to detect prostate cancer with an area under the curve (AUC) of 0.783 and a PPV of 80%. Conclusion: These findings identify a unique expression profile of miRNA detectable in the blood of prostate cancer patients. This confirms their use as a novel, diagnostic biomarker for prostate cancer. MDPI 2015-07-07 /pmc/articles/PMC4519795/ /pubmed/26239681 http://dx.doi.org/10.3390/jcm4071369 Text en © 2015 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Kelly, Brian D.
Miller, Nicola
Sweeney, Karl J.
Durkan, Garrett C.
Rogers, Eamon
Walsh, Killian
Kerin, Michael J.
A Circulating MicroRNA Signature as a Biomarker for Prostate Cancer in a High Risk Group
title A Circulating MicroRNA Signature as a Biomarker for Prostate Cancer in a High Risk Group
title_full A Circulating MicroRNA Signature as a Biomarker for Prostate Cancer in a High Risk Group
title_fullStr A Circulating MicroRNA Signature as a Biomarker for Prostate Cancer in a High Risk Group
title_full_unstemmed A Circulating MicroRNA Signature as a Biomarker for Prostate Cancer in a High Risk Group
title_short A Circulating MicroRNA Signature as a Biomarker for Prostate Cancer in a High Risk Group
title_sort circulating microrna signature as a biomarker for prostate cancer in a high risk group
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4519795/
https://www.ncbi.nlm.nih.gov/pubmed/26239681
http://dx.doi.org/10.3390/jcm4071369
work_keys_str_mv AT kellybriand acirculatingmicrornasignatureasabiomarkerforprostatecancerinahighriskgroup
AT millernicola acirculatingmicrornasignatureasabiomarkerforprostatecancerinahighriskgroup
AT sweeneykarlj acirculatingmicrornasignatureasabiomarkerforprostatecancerinahighriskgroup
AT durkangarrettc acirculatingmicrornasignatureasabiomarkerforprostatecancerinahighriskgroup
AT rogerseamon acirculatingmicrornasignatureasabiomarkerforprostatecancerinahighriskgroup
AT walshkillian acirculatingmicrornasignatureasabiomarkerforprostatecancerinahighriskgroup
AT kerinmichaelj acirculatingmicrornasignatureasabiomarkerforprostatecancerinahighriskgroup
AT kellybriand circulatingmicrornasignatureasabiomarkerforprostatecancerinahighriskgroup
AT millernicola circulatingmicrornasignatureasabiomarkerforprostatecancerinahighriskgroup
AT sweeneykarlj circulatingmicrornasignatureasabiomarkerforprostatecancerinahighriskgroup
AT durkangarrettc circulatingmicrornasignatureasabiomarkerforprostatecancerinahighriskgroup
AT rogerseamon circulatingmicrornasignatureasabiomarkerforprostatecancerinahighriskgroup
AT walshkillian circulatingmicrornasignatureasabiomarkerforprostatecancerinahighriskgroup
AT kerinmichaelj circulatingmicrornasignatureasabiomarkerforprostatecancerinahighriskgroup